Calcitrol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcitrol

Property Description
Active Ingredient Calcitriol (1,25-dihydroxyvitamin D3)
Form Capsule, Oral Solution, Injectable Solution, Topical Ointment
Pharmacological Class Vitamin D Analog, Calcitrophic Hormone
General Purpose Regulates calcium and phosphate levels in the blood
Origin Synthetic, Biologically-Active Metabolite

What is Calcitriol and What Type of Drug is it?

Calcitriol is a prescription-only medicine classified as a potent Vitamin D Analog and a hormone, representing the body's most powerful, active form of vitamin D3. It is the synthetic version of the substance naturally produced in the human body, chemically known as 1alpha,25-dihydroxyvitamin D3. The drug is central to the calcitrophic hormone family, meaning it plays a direct and vital role in the body's mineral regulation systems, an action clinically recognized for its reliable efficacy in maintaining mineral homeostasis. Unlike generic vitamin D3, which requires multiple conversion steps by the liver and kidneys, Calcitriol is administered in its ready-to-use form, bypassing the body's natural activation process.


Calcitriol Composition and Available Forms

The medicine is a single-ingredient product composed solely of the active compound Calcitriol, delivered using various foundational vehicles. To accommodate different medical needs, Calcitriol is available in several high-level Dosage Forms, including soft-gel capsules and oral solutions for ingestion, an injectable solution administered intravenously (IV), and a specific topical ointment for external application. The difference in formulation highlights Calcitriol’s dual-purpose application: it functions systemically to address metabolic bone disorders and locally when used topically. The various forms ensure the active compound can be matched to the patient's specific route of administration.


What is Calcitriol’s General Purpose?

The general purpose of Calcitriol is to function as a crucial signaling agent, directly managing calcium and phosphate levels. This medicine acts as a Vitamin D receptor agonist, promoting the efficient absorption of calcium from the intestinal tract and ensuring minerals are properly processed by the kidneys and bones. This action is essential for maintaining appropriate mineral concentrations in the bloodstream, often used in scenarios where compromised kidney function prevents the body from completing the final necessary step of vitamin D activation. Maintaining this mineral balance is fundamental to supporting bone strength, normal nerve function, and healthy muscle contraction.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Calcitrol?

Calcitriol's safety profile is centered on the risk of elevated calcium levels, which can lead to serious adverse reactions if not carefully managed.

Safety Restrictions and Contraindications

Calcitriol is contraindicated and should not be used in patients with pre-existing hypercalcemia (high calcium levels in the blood) or evidence of vitamin D toxicity. It must not be given with other vitamin D products or derivatives due to the risk of additive effects and severe hypercalcemia.

Serious and Common Adverse Reactions

The most common and clinically significant adverse reaction is hypercalcemia. Chronic, untreated hypercalcemia can lead to severe complications, including generalized vascular calcification and nephrocalcinosis (soft-tissue calcification in the kidneys and elsewhere).

Adverse reactions associated with excessive vitamin D intake are classified by time of onset:

Adverse Reaction Category Examples of Documented Symptoms (System-Organ Classes)
Early Symptoms Weakness, headache, nausea, dry mouth, constipation, muscle or bone pain, metallic taste (Nervous, Gastrointestinal, Musculoskeletal)
Late Symptoms Polyuria (increased urination), polydipsia (increased thirst), anorexia, weight loss, cardiac arrhythmias, ectopic calcification (Metabolic, Renal, Cardiac, General)

Population-Specific Safety Notes

Official regulatory information specifies caution for certain groups: it is classified as Pregnancy Category C, and pregnant individuals require close monitoring of serum calcium. Calcitriol may be excreted into breast milk.

Safety Monitoring

Frequent laboratory monitoring of serum calcium, phosphorus, magnesium, and alkaline phosphatase, as well as 24-hour urinary calcium and phosphorus, is a mandated part of official safety protocols.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Calcitriol is defined by its core physiological effect: inducing hypercalcemia (elevated calcium) and hyperphosphatemia in the body.

Overdose Scope Official Regulatory Statement
Documented Overdose Presentations Symptoms of acute overdose may include early manifestations such as nausea, vomiting, headache, weakness, excessive thirst (polydipsia), and constipation. Laboratory findings include elevated serum calcium and phosphate.
Serious or Severe Outcomes Persistent or chronic hypercalcemia carries the documented risk of severe complications, including cardiac arrhythmias, hypertension, ectopic soft-tissue calcification, and permanent renal failure (nephrocalcinosis).
Population-specific Overdose Notes The risk of severe or complicated hypercalcemia is officially noted as being higher in individuals with pre-existing renal impairment, including patients undergoing chronic renal dialysis.
Antidote Information Regulatory documents indicate that no specific antidote is known for Calcitriol overdose.

When Urgent Medical Help is Required

Seek immediate medical attention or contact emergency services for any suspected overdose or when severe symptoms indicative of hypercalcemia, such as persistent vomiting, profound weakness, or irregular heartbeat, are present. Regulatory guidance mandates the immediate discontinuation of Calcitriol and any associated calcium supplementation, followed by aggressive symptomatic and supportive treatment, including hydration and frequent monitoring of serum electrolytes and cardiac activity (ECG), which may require hospitalization.

Therapeutic Uses of Calcitrol

Quick Facts: Calcitriol

  • Manages low calcium levels (hypocalcemia).
  • Supports patients undergoing chronic renal dialysis.
  • Addresses secondary hyperparathyroidism.
  • Used in conditions like postsurgical hypoparathyroidism.

Calcitriol is a prescription medication utilized in a treatment plan to address conditions related to altered calcium and parathyroid hormone levels in the body.

It is an available therapeutic agent for the management of hypocalcemia (low calcium levels) in adult patients undergoing chronic renal dialysis. For individuals with chronic kidney disease who are not yet on dialysis, it is used to manage secondary hyperparathyroidism and associated metabolic bone conditions. This medication also helps manage hypocalcemia in patients diagnosed with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.

In a topical form, calcitriol is indicated for the management of mild to moderate plaque psoriasis in adults. This application is designed to help improve the appearance of the affected skin areas.

Eligibility and Restrictions for Use

Eligibility Scope: Official Regulatory Information

The eligibility for Calcitriol is strictly defined by regulatory documents, focusing on existing calcium status, age, and comorbidities. Use is officially allowed for populations such as patients undergoing chronic renal dialysis and those with various forms of hypoparathyroidism.

Absolute Contraindications

Calcitriol is contraindicated and must not be used in patients with the following conditions, as they pose a direct, unacceptable risk:

  • Hypercalcemia (high levels of calcium in the blood)
  • Evidence of Vitamin D toxicity
  • Known hypersensitivity to calcitriol or any of its constituent excipients.

Conditional and Restricted Use

Certain populations require special consideration or are not recommended for use:

  • Pediatric Population: Use of the oral capsule is generally not recommended due to insufficient investigation into safety and efficacy, though it is used for specific conditions in older children.
  • Pregnancy: Classified as FDA Category C, use is permitted only if the potential benefit justifies the potential risk to the fetus.
  • Lactation: Breastfeeding is not recommended during therapy, as the medicine may pass into breast milk.
  • Comorbidities: Use requires caution in patients taking digitalis/digoxin due to the risk of cardiac arrhythmias. Concomitant use with magnesium-containing antacids is not recommended for patients on chronic renal dialysis.

What should I know about interactions with other medicines?

Calcitriol's interaction profile is strictly defined by its potent activity as an official regulator of mineral balance, with several combinations categorized as restricted or formally contraindicated in regulatory documents.

Contraindicated Combinations

Co-administration with other Vitamin D Analogs is officially contraindicated due to the high risk of vitamin D toxicity and subsequent hypercalcemia. Separately, magnesium-containing preparations, such as antacids or laxatives, are formally contraindicated for use in patients undergoing chronic renal dialysis due to the danger of hypermagnesemia.

Documented Interaction Patterns

Interactions with Thiazide Diuretics are noted to increase the risk of hypercalcemia by decreasing urinary calcium excretion. Co-administration with Calcium Supplements or Phosphate-Binding Agents requires careful regulatory management to prevent hypercalcemia or hyperphosphatemia, respectively.

Pharmacokinetic interactions are also documented: Bile Acid Sequestrants (e.g., Cholestyramine) may impair Calcitriol absorption in the intestine, officially requiring a time separation between doses. Furthermore, CYP enzyme inducers (e.g., Phenytoin) can reduce Calcitriol serum concentrations, while CYP enzyme inhibitors (e.g., Ketoconazole) may increase exposure.

Mechanism of Action

Calcitriol is the fully activated, hormonal form of vitamin D, and its mechanism is to directly engage the body's genomic mineral regulation system to modulate systemic calcium and phosphate concentrations. The drug acts as an agonist for the Vitamin D Receptor (VDR), an intracellular nuclear receptor expressed in the intestine, kidney, and parathyroid glands.

Direct Regulation of Mineral Transport Capacity

Calcitriol initiates a powerful transcriptional cascade by binding the VDR, which then modifies DNA to upregulate the expression of genes essential for transport, notably Calbindin-D. This process structurally increases the capacity of the intestinal lining to actively absorb and transfer dietary calcium into the bloodstream. This domain is relevant for controlling the supply of mineral input to the systemic pool.

Suppression of the Parathyroid Endocrine Axis

A concurrent and defining feature of the mechanism is the direct suppression of Parathyroid Hormone (PTH) synthesis. The Calcitriol-VDR complex binds directly to the PTH gene promoter in the parathyroid glands, acting as an inhibitor of PTH production and release. This action results in the adjustment of serum calcium levels and limits the PTH-mediated signal for calcium mobilization from the skeleton.

Dosage and Administration Information

How to Use Calcitriol: Official Administration Guidelines

Calcitriol administration is governed by the specific medical condition and available dosage form, necessitating a highly structured protocol.


Administration Routes and Standard Dosing

Administration Route Typical Adult Dosing Pattern Frequency and Schedule
Oral (Capsule or Solution) Initial dose typically 0.25mu g, adjusted over time to a maintenance range of 0.5mu g to 2mu g. Once daily for continuous systemic therapy.
Intravenous (IV) (Injection) Initial dose of 1mu g to 2mu g, adjusted to a maintenance range of 0.5mu g to 4mu g. Three times weekly (intermittent use), administered at the end of a hemodialysis session.
Topical (Ointment) Apply a thin film to the affected area. Maximum weekly dose must not exceed 200 grams. Twice daily (morning and evening).

Contextual Use and Procedural Requirements

Systemic treatment requires patients to maintain adequate daily calcium intake (e.g., 600 mg to 1000 mg daily) to support the medication's intended action. For oral and IV use, the dose is not static but must be titrated (adjusted) based on biochemical response. Increases to the oral dose are typically made in 0.25mu g increments at multi-week intervals (e.g., 4 to 8 weeks). If elevated calcium levels occur during treatment, the dose must be immediately discontinued and then resumed at a lower amount once normal levels are achieved. For pediatric patients, the maximum weekly dose of the topical ointment is reduced (100 grams for children 2–6 years). The injectable solution is administered as a rapid bolus and requires no dilution. Topical use is restricted and must not be applied to the face, eyes, or mucous membranes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calcitriol

The available research evidence on Calcitriol is drawn from clinical evaluations of the medicine in specific conditions, primarily studying its effects on mineral metabolism and, in topical form, for skin conditions. This overview summarizes the structure of the regulatory-supporting research, detailing the types of studies conducted and what researchers monitored.


Evidence for Use in Low Calcium Levels During Chronic Renal Dialysis

The evidence base for Calcitriol in patients undergoing chronic renal dialysis is supported by Randomized Controlled Trials (RCTs) and various observational cohorts. Researchers primarily examined short-term changes in biomarkers, focusing on outcomes related to systemic or functional imbalance. In these studies, researchers monitored measurements of serum calcium concentrations and assessed the status of elevated parathyroid hormone (PTH) levels. Findings describe patterns observed in these short-term studies, reporting that the medicine was observed in some studies to modify these levels.


Evidence for Secondary Hyperparathyroidism in Chronic Kidney Disease

Research for secondary hyperparathyroidism (SHPT) includes robust evidence from RCTs, comparative trials against other Vitamin D analogs, and comprehensive systematic reviews. These trials studied adult patients with various stages of CKD. The studies monitored outcomes linked to hormonal regulation, primarily focusing on the capacity of the medicine to achieve a reduction in PTH levels. Research highlights changes measured during the study period, reporting that stabilization of PTH levels was observed in some studies.


Research on Hypocalcemia in Hypoparathyroidism

Research exploring Calcitriol in individuals with hypoparathyroidism is built on small-scale randomized trials and long-term open-label extension studies. Researchers examined the capacity for the medicine to maintain and stabilize serum calcium levels and closely monitored urinary calcium excretion, which is an outcome that research monitors for its relationship to long-term renal function. Limited information for long-term outcomes exists, particularly when research is compared to findings involving hormone replacement therapy.


Evidence for Topical Use in Plaque Psoriasis

The evidence for the topical ointment formulation is centered on multicenter, randomized, double-blind, vehicle-controlled studies. The primary outcomes studied related to physical discomfort and inflammatory states, where researchers monitored changes using objective dermatologic scores. Research highlights changes measured during the short-term study period, typically up to eight weeks, reporting that the observed populations experienced changes in specific skin scores compared to the application of the inactive vehicle.


What is Still Uncertain About Calcitriol Research

Key limitations in the research include the prevalence of studies that prioritize biochemical endpoints (like PTH levels) over hard clinical outcomes (like fracture prevention). Comparative evidence against a full range of alternative treatments remains limited for all approved research indications. Finally, the research consistently identifies the observation of high calcium and phosphate levels as a pattern observed in the studies, which remains a key focus of ongoing research.

Key Studies & References

  1. Calcitriol - StatPearls (NCBI Bookshelf) - Indications and Evidence Summary
  2. Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) - StatPearls (NCBI Bookshelf)
  3. Calcitriol Ointment 3 $mu$g/g Is Safe and Effective Over 52 Weeks for the Treatment of Mild to Moderate Plaque Psoriasis (Long-term Safety Study)
  4. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD)

Frequently Asked Questions (FAQ)

Common questions about Calcitrol (FAQ)

Q: What is Calcitrol?

Calcitrol is the active form of vitamin D (also known as 1,25-dihydroxycholecalciferol or 1,25( OH)2 D3). It is a hormone that plays a crucial role in regulating the amount of calcium and phosphate in the body, which are essential for strong bones and healthy parathyroid function.

Q: How does Calcitrol work?

Calcitrol works by increasing the absorption of calcium from the gut (intestine). It also helps the kidneys reabsorb calcium and works with the parathyroid hormone to manage bone growth and mineralization. This helps maintain healthy levels of calcium in the bloodstream.

Q: What conditions is Calcitrol used to treat?

Calcitrol is primarily used to treat conditions associated with a deficiency in active vitamin D and low calcium levels, such as:

  • Chronic kidney disease (renal osteodystrophy or secondary hyperparathyroidism)
  • Hypoparathyroidism (a condition where the parathyroid glands don't produce enough parathyroid hormone, leading to low blood calcium)
  • Vitamin D-resistant rickets (familial hypophosphatemia)

Q: How should Calcitrol be stored?

Calcitrol capsules should be stored at room temperature (between 59 F and 86 F or 15 C and 30 C), away from moisture and direct heat. Keep the medication in its original container and make sure the bottle is tightly closed.

Q: What are the potential side effects of Calcitrol?

The most common and significant side effect of Calcitrol is the development of hypercalcemia (high levels of calcium in the blood), which is often dose-related. Early symptoms of hypercalcemia can include:

  • Nausea and vomiting
  • Constipation
  • Tiredness or weakness
  • Headache
  • Dry mouth
  • Increased thirst and urination

If hypercalcemia is severe or lasts a long time, it can cause more serious issues like kidney damage. Regular blood monitoring is necessary to keep calcium levels in a safe range.

Q: Can Calcitrol be taken with other medications?

Calcitrol may interact with several types of medications, potentially affecting its efficacy or increasing the risk of side effects, especially hypercalcemia. It is important to inform a healthcare provider of all medications and supplements being taken, particularly:

  • Thiazide diuretics ('water pills')
  • Digitalis (digoxin)
  • Magnesium-containing antacids
  • Other vitamin D supplements or derivatives
  • Bile acid sequestrants (e.g., cholestyramine)

Q: What is the significance of serum calcium monitoring while on Calcitrol?

Monitoring serum calcium (calcium levels in the blood) is critical when taking Calcitrol. Since Calcitrol increases calcium absorption, the primary risk is hypercalcemia (too much calcium). Regular blood tests allow the healthcare provider to adjust the dose promptly to prevent this serious side effect and ensure the medication is working effectively and safely.

How should Calcitrol be stored and disposed of?

How to Store and Dispose of Calcitriol

Official regulatory documents mandate strict conditions for the storage and disposal of calcitriol to maintain its stability.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). The injectable solution must not be frozen.
Protection Keep the medicine protected from light and moisture.
Container Keep in the original container and ensure it is tightly closed.
Safety All formulations must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired calcitriol must be disposed of in accordance with local requirements. The container and any unused contents of the injectable solution are specifically restricted from being put into sewer or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcitrol found in:

A-Z Index: